Back to News

American Academy of Ophthalmology 2020 – Virtual

LUMEVOQ® (GS010) – Leber’s Hereditary Optic Neuropathy (LHON) 

Paper Title – Efficacy of Gene Therapy for Leber Hereditary Optic Neuropathy: Final Results of the Phase 3 RESCUE and REVERSE Trials Abstract Number:  30064033 Presenting Author:  Patrick Yu-Wai-Man, FRCOphth, MBBS, PHD, Senior Lecturer and Honorary Consultant Ophthalmologist at the University of Cambridge, Moorfields Eye Hospital, and the UCL Institute of Ophthalmology, London (UK) Session:  PA030 Topic:  Neuro-Ophthalmology Date – Time:  Available On Demand  

GS030 – Optogenetics in Retinitis Pigmentosa

Paper Title – Optogenetics in the Clinic: PIONEER, a Phase 1/2 Gene Therapy Program for Non syndromic RP Abstract Number:  30064259 Presenting Author:  Joseph N Martel MD, Assistant Professor of Ophthalmology Retina and Vitreous Servious, UPMC Eye Center – Eye & Ear Institute, Pittsburg, PA (US) Session:  PA056 Topic:  Retina, Vitreous date – Time:  Available On Demand  
Back to News

A New Chapter

Founded in 2012 to realize the potential of gene therapy, GenSight Biologics has grown into a clinical-stage company advancing multiple programs. In 2024, under a new management team, the company entered a new phase and is now accelerating its clinical and regulatory activities.

Explore investors’ hub

GenSight Biologics S.A.
74 rue du Faubourg Saint-Antoine
75012 Paris
France